WASHINGTON DC (May 31, 2018) – AAM applauds FDA for issuing these guidances to address one form of brand gamesmanship that has delayed generic and biosimilar competition and price reductions for patients. Calls for voluntary action by brand companies to stop their efforts to thwart generic competition are not enough. It is time for Congress to pass the CREATES Act, which will help put an end to these types of abuses and free up the generic and biosimilar competition the president is prioritizing in his American Patients First platform.
ATTRIBUTE TO: Chip Davis, AAM President and CEO
MEDIA CONTACT:
Rachel Schwartz
202.249.7147 (o)
202.251.8881 (c)